• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

6.080 -0.090 (-1.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,022,797
Open 6.000
Bid (Size) 6.000 (2)
Ask (Size) 6.200 (1)
Prev. Close 6.170
Today's Range 5.880 - 6.330
52wk Range 2.100 - 9.100
Shares Outstanding 44,784,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
July 29, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
July 24, 2025
From Verastem Oncology
Via Business Wire

Performance

YTD
-6.3%
-6.3%
1 Month
+25.4%
+25.4%
3 Month
-18.2%
-18.2%
6 Month
N/A
N/A
1 Year
+150.2%
+150.2%

More News

Read More
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
July 11, 2025
From Verastem Oncology
Via Business Wire
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
July 08, 2025
Via FinancialNewsMedia
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2025
From Verastem Oncology
Via Business Wire
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
July 08, 2025
From FN Media Group LLC
Via GlobeNewswire
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
June 30, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
June 24, 2025
From Verastem Oncology
Via Business Wire
Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish
June 02, 2025
Via Stocktwits
12 Health Care Stocks Moving In Monday's Intraday Session
June 02, 2025
Via Benzinga
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May
June 02, 2025
Via Benzinga
What's Going On With Verastem Oncology Stock On Monday?
June 02, 2025
Via Benzinga
Which stocks are experiencing notable movement on Monday?
June 02, 2025
Via Chartmill
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
June 02, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
May 28, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
May 22, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
May 13, 2025
From Verastem Oncology
Via Business Wire
FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer
May 08, 2025
Via Benzinga
Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased
May 08, 2025
Via Stocktwits
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
May 08, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at Upcoming Investor Conferences
May 01, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces $75 million Private Placement
April 25, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
April 23, 2025
From Verastem Oncology
Via Business Wire
9 Health Care Stocks With Whale Alerts In Today's Session
April 22, 2025
Via Benzinga
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
April 10, 2025
Via Benzinga

Frequently Asked Questions

Is Verastem, Inc. - Common Stock publicly traded?
Yes, Verastem, Inc. - Common Stock is publicly traded.
What exchange does Verastem, Inc. - Common Stock trade on?
Verastem, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verastem, Inc. - Common Stock?
The ticker symbol for Verastem, Inc. - Common Stock is VSTM on the Nasdaq Stock Market
What is the current price of Verastem, Inc. - Common Stock?
The current price of Verastem, Inc. - Common Stock is 6.080
When was Verastem, Inc. - Common Stock last traded?
The last trade of Verastem, Inc. - Common Stock was at 08/01/25 04:00 PM ET
What is the market capitalization of Verastem, Inc. - Common Stock?
The market capitalization of Verastem, Inc. - Common Stock is 272.29M
How many shares of Verastem, Inc. - Common Stock are outstanding?
Verastem, Inc. - Common Stock has 272M shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap